Adverse events after first and second doses of COVID-19 vaccination in England : a national vaccine surveillance platform self-controlled case series study
OBJECTIVES: To estimate the incidence of adverse events of interest (AEIs) after receiving their first and second doses of coronavirus disease 2019 (COVID-19) vaccinations, and to report the safety profile differences between the different COVID-19 vaccines.
DESIGN: We used a self-controlled case series design to estimate the relative incidence (RI) of AEIs reported to the Oxford-Royal College of General Practitioners national sentinel network. We compared the AEIs that occurred seven days before and after receiving the COVID-19 vaccinations to background levels between 1 October 2020 and 12 September 2021.
SETTING: England, UK.
PARTICIPANTS: Individuals experiencing AEIs after receiving first and second doses of COVID-19 vaccines.
MAIN OUTCOME MEASURES: AEIs determined based on events reported in clinical trials and in primary care during post-license surveillance.
RESULTS: A total of 7,952,861 individuals were vaccinated with COVID-19 vaccines within the study period. Among them, 781,200 individuals (9.82%) presented to general practice with 1,482,273 AEIs. Within the first seven days post-vaccination, 4.85% of all the AEIs were reported. There was a 3-7% decrease in the overall RI of AEIs in the seven days after receiving both doses of Pfizer-BioNTech BNT162b2 (RI = 0.93; 95% CI: 0.91-0.94) and 0.96; 95% CI: 0.94-0.98), respectively) and Oxford-AstraZeneca ChAdOx1 (RI = 0.97; 95% CI: 0.95-0.98) for both doses), but a 20% increase after receiving the first dose of Moderna mRNA-1273 (RI = 1.20; 95% CI: 1.00-1.44)).
CONCLUSIONS: COVID-19 vaccines are associated with a small decrease in the incidence of medically attended AEIs. Sentinel networks could routinely report common AEI rates, which could contribute to reporting vaccine safety.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Journal of the Royal Society of Medicine - (2023) vom: 03. Nov., Seite 1410768231205430 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tsang, Ruby Sm [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Epidemiology |
|---|
| Anmerkungen: |
Date Revised 03.11.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1177/01410768231205430 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364133937 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364133937 | ||
| 003 | DE-627 | ||
| 005 | 20231226094812.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/01410768231205430 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1213.xml |
| 035 | |a (DE-627)NLM364133937 | ||
| 035 | |a (NLM)37921538 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tsang, Ruby Sm |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adverse events after first and second doses of COVID-19 vaccination in England |b a national vaccine surveillance platform self-controlled case series study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a OBJECTIVES: To estimate the incidence of adverse events of interest (AEIs) after receiving their first and second doses of coronavirus disease 2019 (COVID-19) vaccinations, and to report the safety profile differences between the different COVID-19 vaccines | ||
| 520 | |a DESIGN: We used a self-controlled case series design to estimate the relative incidence (RI) of AEIs reported to the Oxford-Royal College of General Practitioners national sentinel network. We compared the AEIs that occurred seven days before and after receiving the COVID-19 vaccinations to background levels between 1 October 2020 and 12 September 2021 | ||
| 520 | |a SETTING: England, UK | ||
| 520 | |a PARTICIPANTS: Individuals experiencing AEIs after receiving first and second doses of COVID-19 vaccines | ||
| 520 | |a MAIN OUTCOME MEASURES: AEIs determined based on events reported in clinical trials and in primary care during post-license surveillance | ||
| 520 | |a RESULTS: A total of 7,952,861 individuals were vaccinated with COVID-19 vaccines within the study period. Among them, 781,200 individuals (9.82%) presented to general practice with 1,482,273 AEIs. Within the first seven days post-vaccination, 4.85% of all the AEIs were reported. There was a 3-7% decrease in the overall RI of AEIs in the seven days after receiving both doses of Pfizer-BioNTech BNT162b2 (RI = 0.93; 95% CI: 0.91-0.94) and 0.96; 95% CI: 0.94-0.98), respectively) and Oxford-AstraZeneca ChAdOx1 (RI = 0.97; 95% CI: 0.95-0.98) for both doses), but a 20% increase after receiving the first dose of Moderna mRNA-1273 (RI = 1.20; 95% CI: 1.00-1.44)) | ||
| 520 | |a CONCLUSIONS: COVID-19 vaccines are associated with a small decrease in the incidence of medically attended AEIs. Sentinel networks could routinely report common AEI rates, which could contribute to reporting vaccine safety | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Epidemiology | |
| 650 | 4 | |a public health | |
| 650 | 4 | |a vaccination programmes | |
| 700 | 1 | |a Agrawal, Utkarsh |e verfasserin |4 aut | |
| 700 | 1 | |a Joy, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Byford, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Robertson, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Anand, Sneha N |e verfasserin |4 aut | |
| 700 | 1 | |a Hinton, William |e verfasserin |4 aut | |
| 700 | 1 | |a Mayor, Nikhil |e verfasserin |4 aut | |
| 700 | 1 | |a Kar, Debasish |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, John |e verfasserin |4 aut | |
| 700 | 1 | |a Victor, William |e verfasserin |4 aut | |
| 700 | 1 | |a Akbari, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Bradley, Declan T |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, Siobhan |e verfasserin |4 aut | |
| 700 | 1 | |a O'Reilly, Dermot |e verfasserin |4 aut | |
| 700 | 1 | |a Owen, Rhiannon K |e verfasserin |4 aut | |
| 700 | 1 | |a Chuter, Antony |e verfasserin |4 aut | |
| 700 | 1 | |a Beggs, Jillian |e verfasserin |4 aut | |
| 700 | 1 | |a Howsam, Gary |e verfasserin |4 aut | |
| 700 | 1 | |a Sheikh, Aziz |e verfasserin |4 aut | |
| 700 | 1 | |a Richard Hobbs, F D |e verfasserin |4 aut | |
| 700 | 1 | |a Lusignan, Simon de |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the Royal Society of Medicine |d 1978 |g (2023) vom: 03. Nov., Seite 1410768231205430 |w (DE-627)NLM00025701X |x 1758-1095 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:03 |g month:11 |g pages:1410768231205430 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/01410768231205430 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 03 |c 11 |h 1410768231205430 | ||